Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

258.15
-4.7500-1.81%
Post-market: 258.150.00000.00%16:08 EDT
Volume:4.23M
Turnover:1.09B
Market Cap:456.25B
PE:72.93
High:262.50
Open:260.81
Low:257.25
Close:262.90
52wk High:267.47
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:0.99
T/O Rate:0.24%
Dividend:6.83
Dividend Rate:2.65%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-76.87
PE(LYR):109.39

Loading ...

AbbVie’s ABBV-313 Phase 1 Trial: What Early Safety Work Means for Investors

TIPRANKS
·
Jul 25

AbbVie Advances Nacresertib With Key Drug–Drug Interaction Study

TIPRANKS
·
Jul 25

Netflix, AbbVie, Cerebras Systems And An Energy Stock On CNBC’s ‘Final Trades’

Benzinga_recent_news
·
Jul 24

Ema's Chmp: Recommends Granting Marketing Authorisation for Icotyde

THOMSON REUTERS
·
Jul 24

Earning Preview: AbbVie Q2 revenue is expected to increase by 11.54%, and institutional views are bullish

Earnings Agent
·
Jul 24

Stocks to Watch: Intel, Deckers, Edwards Lifesciences, Genmab

Dow Jones
·
Jul 24

Genmab, Abbvie Say Lymphoma Drug Failed to Meet Primary Endpoint in Phase 3 Trial

Dow Jones
·
Jul 24

Abbvie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 24

Genmab, Abbvie Clarify Primary Endpoints in Phase 3 Epcore Dlbcl-1 Trial

Reuters
·
Jul 24

Genmab: Clarify Overall Survival (os) was Sole U.S. Primary Endpoint in Phase 3 Epcore(®) Dlbcl-1 Trial and was not Met

THOMSON REUTERS
·
Jul 24

Genmab and Abbvie Provide Clarification on Phase 3 Epcore® Dlbcl-1 Trial Evaluating Epcoritamab (duobody®-cd3xcd20) in Patients with Relapsed/refractory Diffuse Large B-cell Lymphoma (dlbcl)

THOMSON REUTERS
·
Jul 24

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

GlobeNewswire
·
Jul 24

Analysts Offer Insights on Healthcare Companies: Integer Holdings (ITGR), Thermo Fisher (TMO) and AbbVie (ABBV)

TIPRANKS
·
Jul 23

Abbvie Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Jul 23

Canaccord Genuity Adjusts Price Target on AbbVie to $282 From $273, Maintains Buy Rating

MT Newswires Live
·
Jul 22

Abbvie is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Jul 22

U.s. Research Roundup-danaher, Gm, Msci

Reuters
·
Jul 22

Therapeuticsmd Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 21

AbbVie’s ABBV-8736 Injection Study Signals Quiet But Meaningful Pipeline Progress

TIPRANKS
·
Jul 21

European Equities Mixed in Friday Trading; ASML to Give Staff One-Time Bonus

MT Newswires Live
·
Jul 17